Research
Hormonal
Combination pharmacotherapy for obesity is significantly more effective than monotherapy.
If one weight loss medication isn't working well, ask your doctor about combination therapies. They combine two drugs to target different pathways, often resulting in greater weight loss than a single drug.
ModerateSupportsMEDIUM confidence
Combination pharmacotherapy is increasingly being adopted worldwide for obesity treatment due to its heightened efficacy and beneficial outcomes... Therefore, combination therapies are not only more efficacious in treating obesity but also have more long-lasting effects than monotheries.
Why this rating
Based on cited studies showing efficacy, but often smaller sample sizes or shorter durations than top-tier drugs.
Source
Obesity and Current Treatment Approaches: A Comprehensive Review
Karthik Mathialagan et al. · Journal of Translational Gastroenterology · 2024
DOI 10.14218/jtg.2023.00040
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly subcutaneous semaglutide (2.4 mg) produces significantly greater mean weight loss (15.4%) compared to daily subcutaneous liraglutide (3.0 mg, 6.4%) in patients with overweight or obesity.Good
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than Semaglutide in patients with type 2 diabetes.Good
- Bariatric surgery (Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) provides effective and sustainable weight loss, with Roux-en-Y showing greater long-term excess weight loss but higher morbidity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →